NERVGEN PHARMA CORP.
NERVGEN PHARMA CORP. (NGEN): 1 pipeline candidate · ~3 mo cash runway · 1 clinical trial. Updated within the last hour.
BioSniper Score
4-factor signal · derived from public data
3.4 months
D/E 5.68 · 0% dilution
Lead: Phase 1/Phase 2
1 candidate
N/A
N/A
A transparent, data-derived signal for NERVGEN PHARMA CORP.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$212.4M
Cash
$22.1M
Quarterly Burn
$19.5M
Runway
3.4 mo
Revenue
—
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (1 candidate)
| Drug | Phase |
|---|---|
| nvg-291 | Phase 1/Phase 2 |
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
41
Total value held
$5.6M
| Holder | Shares | Value |
|---|---|---|
| pfg investments, llc | 201,000 | $758K |
| bank of america corp /de/ | 200,656 | $756K |
| marshall wace, llp | 200,359 | $755K |
| royal bank of canada | 171,961 | $648K |
| valley forge investment consultants inc adv | 77,698 | $293K |
| bank of montreal /can/ | 62,900 | $237K |
| captrust financial advisors | 62,367 | $235K |
| osaic holdings, inc. | 39,991 | $151K |
| patriot financial group insurance agency, llc | 37,000 | $139K |
| commonwealth equity services, llc | 33,350 | $126K |
Showing top 10 of 41 institutional holders of NERVGEN PHARMA CORP.. Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
How many drug candidates are in NERVGEN PHARMA CORP.'s pipeline?
NERVGEN PHARMA CORP. (NGEN) has 1 pipeline candidate tracked by BioSniper across SEC filings and clinical trial registrations.
What is NERVGEN PHARMA CORP.'s lead drug candidate?
NERVGEN PHARMA CORP.'s most advanced tracked candidate is nvg-291 (Phase 1/Phase 2) for Spinal Cord Injuries.
What is NERVGEN PHARMA CORP.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, NERVGEN PHARMA CORP. has approximately 3.4 months of cash runway.
What is NERVGEN PHARMA CORP.'s market capitalization?
NERVGEN PHARMA CORP.'s market capitalization is approximately $212.4M.
Who is the CEO of NERVGEN PHARMA CORP.?
Dr. Adam H. Rogers M.D. is the chief executive officer of NERVGEN PHARMA CORP. (NGEN).
Get the full picture on NERVGEN PHARMA CORP.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.